Author Archives: Millie Nelson

Wockhardt and Serum to construct plant in UK

Wockhardt and Serum Life Sciences UK have partnered to build a facility in Wrexham, Wales to manufacture various vaccines. Wockhardt, headquartered in Mumbai, India said the collaboration with Serum Life Sciences UK (a subsidiary of the Serum Institute of India) will deliver an additional 150 million doses of a wide range of vaccines through building a fill-finish facility in Wrexham, North Wales. “We are delighted to have formed a strategic partnership between Wockhardt and Serum Life Sciences. The collaboration will…

WuXi Bio grabs larger piece of the bio CDMO pie

With over 10% of the biologics outsourcing market share, WuXi Biologics is now the second largest CDMO according to an analyst.  The China-based contract development manufacturing organization (CDMO) reported its end of year results for 2021. Revenues increased by 83.3% year-on-year to $1.6 billion and net profits grew by 107%, totaling $550 million. Furthermore, according to Chris Liu, an equity analyst at Jefferies, Wuxi is now the second largest player in the global biologics outsourcing market with 10.3% shares of…

Shape Therapeutics: ‘We’ve engineered a new kind of RNA’

Shape Therapeutics says its research on RNA editing technology could make it easier to repair disease-causing mutations without compromising efficiency. Prashant Mali, the co-founder of Shape, and his colleagues claim they have engineered a “new kind of guide RNA” that can recruit the cell’s own ADARs (an enzyme naturally found in the human body) to carry out edits at a precise target RNA region. According to Shape, ADARs have the ability to alter the RNA code and correct G-to-A mutations,…

Californian CDMO triples iPS capacity with $10m investment

I Peace has invested over $10 million to expand its Palo Alto, California plant, tripling capacity to manufacture iPS and iPSC-derived differentiated cells. I Peace, a contract development manufacturing organization (CDMO) start-up, has tripled its capacity to produce induced pluripotent stem (iPS) cells and induced pluripotent stem cells (iPSC) by expanding its facility. The firm claims that the plant expansion will meet the demand for iPS cells from pharmaceutical companies and cell therapy manufacturers, as well as providing individuals with…

Catalent completes $30m project at French facility

Catalent has expanded its Limoges, France site to fulfil clinical biologics formulation development and drug product fill/finish services. Contract development manufacturing organization (CDMO) Catalent announced its plans to invest $30 million in July 2020. Now, the firm has completed the project and says the Limoges plant will widen its global network, with clinical development through to clinical supply services and small-scale commercial manufacturing. “Catalent continues to look for ways to support its customers as they advance projects to the clinic…

Ginkgo adds cell programming platform with FGen buy

Ginkgo Bioworks says the acquisition of Swiss start-up FGen will significantly increase its cell screening capabilities.   The deal, of which specific financial details have not been disclosed, sees Ginkgo add FGen’s technology to its existing screening systems. “Acquiring FGen substantially enhances Ginkgo’s platform by complementing our […] automation-powered high throughput arrayed screening systems,” Nikos Reppas, senior director of Foundry Technology at Ginkgo told BioProcess Insider. “More specifically, FGen’s technology greatly widens […] our Design-Build-Test-Learn strain development cycle, allowing us…

Stevanato to form a manufacturing hub in China

Stevanato Group says its decision to acquire a facility in Zhangjiagang, China is part of its growth strategy and aim to deliver supply chain security. Stevanato, a provider of drug delivery, drug containment, and diagnostic solutions to the life sciences industry, has acquired a facility located close to its plant in the Jiangsu Zhangjiagang Economic and Technical Development Zone. “[Our] facility in Zhangjiagang will support the production of high-value solutions, such as pre-sterilized EZ-fill syringes and vials, meeting the growing…

Nutcracker to advance ‘first-of-its-kind’ biochip-based RNA platform

Nutcracker Therapeutics has raised $167 million in Series C financing to expand its mRNA pipeline and refine its RNA platform. Nutcracker focuses on developing RNA therapeutics using its biochip-based manufacturing platform. The firm claims the financing, led by ARCH Venture Partners, will enable the company to grow its pipeline of messenger RNA (mRNA) medicines for cancer and advance its platform technology. According to Nutcracker, producing RNA-based therapeutics with scalability and speed has remained a constant challenge in the industry. To…

Thermo Fisher shells out $97m to expand clinical research labs

The $97 million investment will expand Thermo Fisher’s bioanalytical laboratory operations into three locations in the Greater Richmond, Virginia region. According to Thermo Fisher Scientific, the decision to expand its clinical research business is in response to increased demand for its services. The investment will see the firm add nearly 150,000 square feet to its Richmond area operations. The laboratories in this location were gained through the firm’s acquisition of contract research organization (CRO) PPD last year. The company is…

UK Gov invests £60m to bolster life sciences manufacturing

The UK government has pledged £260 million to bolster healthcare research, £60 million of which will be used to expand manufacturing capabilities. At the beginning of this month, the UK government announced that £260 million ($339 million) will be invested into the life sciences industry. The £60 million ($78 million) dedicated to expanding manufacturing services will support cell and gene therapies, medical devices, and commercial scale production investments by various companies. The investment for manufacturing fundings will be distributed through…